Trinity Biotech (TRIB) unveils its new flagship product, CGM+, a next-generation wearable biosensor platform designed for the AI wearables market. Now in the later stages of device development, CGM+ is Trinity’s new AI-native continuous glucose monitoring system, combining multi-sensor data and real-time analytics to meet the evolving demands of AI-powered healthcare and wellness.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech Achieves Profitability Milestone Amid Strategic Turnaround
- Trinity Biotech reports Q1 revenue $7.6M
- Trinity Biotech reaches profitability inflection point, marks major milestone
- Trinity Biotech Gains WHO Approval for Outsourced HIV Test Manufacturing
- Trinity Biotech received WHO approval for offshored, outsources manufacturing